Francesca Bonifazi
Overview
Explore the profile of Francesca Bonifazi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
161
Citations
2165
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
La Rocca U, Ricci R, Piciocchi A, Barberi W, Oldani E, Dominietto A, et al.
Blood Transfus
. 2025 Feb;
PMID: 39949023
Background: Antibodies directed against donor-specific HLA allele(s)/antigen(s) (DSAs) represent a known risk factor for hematopoietic stem cell transplantation (HSCT) engraftment. Still, the overall management needs to be standardized. Material And...
2.
Raiola A, Bruno B, Risitano A, Mosna Dr F, Cavattoni I, Onida F, et al.
Blood Adv
. 2025 Feb;
PMID: 39928954
Post-transplant high-dose cyclophosphamide (PTCy) is effective in overcoming the negative impact of HLA disparity in the haploidentical setting. In the light of these results, we investigated the efficacy and safety...
3.
Stella F, Pennisi M, Chiappella A, Casadei B, Bramanti S, Ljevar S, et al.
Transplant Cell Ther
. 2025 Jan;
PMID: 39870308
Background: Anti-CD19 CAR T-cells have revolutionized outcomes in relapsed/refractory large B-cell lymphomas. Long-term follow-up underscored the role of hematological toxicity in nonrelapse mortality, largely driven by infections, leading to the...
4.
Stella F, Chiappella A, Magni M, Bonifazi F, De Philippis C, Musso M, et al.
Br J Haematol
. 2024 Dec;
206(2):644-651.
PMID: 39710966
Brexucabtagene autoleucel (brexu-cel) has revolutionized the treatment of patients affected by mantle cell lymphomas. In this prospective, observational multicentre study, we evaluated 106 patients, with longitudinal brexu-cel kinetics in peripheral...
5.
De Matteis S, Del Coco L, Castro F, Giudetti A, Casadei B, Iannotta F, et al.
Haematologica
. 2024 Dec;
PMID: 39704157
Plasma metabolomics analysis was performed on 44 patients with relapsed/refractory B-cell non-Hodgkin lymphoma (r/r/B-NHL) infused with approved CD19.CAR-T cell products at the time of pre-lymphodepletion (PLD) and at day +1,...
6.
Pellegrini C, Ravaioli F, De Fanti S, Pirazzini C, DSilva C, Garagnani P, et al.
Diagnostics (Basel)
. 2024 Nov;
14(22).
PMID: 39594207
: Neuronal loss is a major pathological feature of neurodegenerative diseases. The analysis of plasma cell-free DNA (cfDNA) is an emerging approach to track cell death events in a minimally...
7.
Ursi M, Kwiatkowska K, Pirazzini C, Storci G, Messelodi D, Bertuccio S, et al.
Haematologica
. 2024 Oct;
110(2):481-484.
PMID: 39363850
No abstract available.
8.
Stella F, Chiappella A, Casadei B, Bramanti S, Ljevar S, Chiusolo P, et al.
Blood Cancer Discov
. 2024 Jul;
5(5):318-330.
PMID: 38953781
This real-world prospective observational study across 21 Italian centers (CART-SIE) compares axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) outcomes in 485 patients with relapsed/refractory large B-cell lymphoma with baseline characteristics matched...
9.
Storci G, De Felice F, Ricci F, Santi S, Messelodi D, Bertuccio S, et al.
J Clin Invest
. 2024 Jun;
134(14).
PMID: 38833312
BACKGROUNDPredicting immune effector cell-associated neurotoxicity syndrome (ICANS) in patients infused with CAR T cells is still a conundrum. This complication, thought to be consequent to CAR T cell activation, arises...
10.
Di Staso R, Casadei B, Gentilini M, Guadagnuolo S, Pellegrini C, Broccoli A, et al.
Ann Hematol
. 2024 May;
103(7):2499-2509.
PMID: 38695872
Poor literature report actual and detailed costs of chimeric antigen receptor (CAR) T-cell pathway in a real-life setting. We retrospectively collect data for all patients with relapsed/refractory aggressive large B-cell...